• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Australia Market
    Australia News
    Australia Stocks
    • Australia Market
    • Australia News
    • Australia Stocks
    1. Home>
    2. Australia Investing>
    Loading...
    0

    Australia Cannabis Update: H1 2021 in Review

    Bryan Mc Govern
    Aug. 24, 2021 01:30PM PST

    In the first half of 2021, Australia's cannabis industry was defined by gradual progress from its stakeholders.

    cannabis grinder full with plant

    Australia's cannabis space has been moving forward, and progress continued in the first half of 2021.

    The country has seen the growth of domestic players, as well as critical changes to the rules surrounding CBD. But at the same time, there are still serious challenges present in the industry.

    In this update, the Investing News Network (INN) takes a closer look at the Australian cannabis market in the first part of the year.


    Australia cannabis update: Domestic market makes progress

    Australia's cannabis industry is defined by its domestic medical market and the international opportunities available for companies in the country. When it comes to the country itself, the sector has grown off the back of increasing patient numbers.

    In its 2021 half-year update, data firm FreshLeaf Analytics said the country was home to 45,000 active patients, with that number expected to reach 75,000 by the end of the year.

    "The Australian medicinal cannabis market continues its strong growth trajectory," Cassandra Hunt, managing director of FreshLeaf Analytics, said in a statement, according to a report from MJBizDaily.

    The document indicates that 2021 is set to bring "evolution in the regulatory landscape," alongside further focus on product quality. The researchers also expect to see additional investment in research and development, as well as "further industry consolidation."

    There's been rapid growth in the number of products available to patients and in revenue for the industry, according to the Australian researchers.

    "Year-to-date sales in 2021 have already surpassed full year revenues in 2019," the report states.

    New research also shows the potential for more consumers to appear if cannabis were to be fully legalised.

    Research from the National Drug and Alcohol Research Centre and UNSW Sydney indicates that 4 percent of Australians would try the drug if it was legalised.

    Australia cannabis update: CBD rule changes provide key progress

    Changes confirmed by the Therapeutic Goods Administration at the end of 2020 came into effect in 2021 as Australia moved forward with allowing the sale of low-dose CBD products over the counter.

    The new rules, which went into effect in February of this year, signalled an evolution in the methodology and evaluation of cannabis in the country.

    "I think what it does is gives the industry and products additional credibility — it builds a level of trust with patients in the market," Stephen Murphy, co-founder of Prohibition Partners, previously told INN.

    However, there are still stringent guidelines for how consumers can access these products. The other current challenge is the arduous process for getting CBD products approved.

    That means this victory for the market won't factor into the industry's financial results this year. Indeed, in its half-year report, FreshLeaf Analytics indicates that it did not count CBD products in its 2021 calculation.

    "It should be noted that these forecasts exclude Schedule 3 low-dose CBD products given that it is unlikely products will be available in 2021," the firm explains.

    The researchers did provide an expectation for these products — they expect to see "pharmacist-only CBD" reach AU$250 million in value at its peak thanks to 2 million consumers.

    "Speed to market will be a critical competitive advantage for those looking to tap into this new and lucrative market," the report from FreshLeaf Analytics notes.

    Australia cannabis update: Ongoing challenges in the industry

    Jo Patterson, CEO of BOD Australia (ASX:BDA), told Business Insider Australia that regulators in the country are directly responsible for the delays holding back the industry.

    "There's limited opportunities here in Australia, because of the regulatory restrictions and mandates," Patterson said to the news outlet.

    Dr. Ben Jansen, a clinical director and founder of cannabis provider and consultancy CDA Clinics, told Business Insider Australia the industry is just now emerging.

    "We're now moving to a point where there are less barriers for people to access cannabis products and CBD products in Australia," Jansen said.

    The struggles are also affecting patients. According to a report from the Australian Associated Press, the Chronic Pain Australia group has found doctors tend to shy away from recommending cannabis medicine.

    A survey of 2,233 Australians shows that despite questions and interest from patients, general practitioners struggle to provide cannabis solutions.

    A medical expert noted that Australian doctors today may not feel comfortable talking about and recommending cannabis to patients if they didn't learn about it in school.

    "Education around the therapeutic activity of cannabis and the endocannabinoid system should be embedded in the medical curriculum and not just offered as a postgraduate choice," Justin Sinclair, a naturopath from Western Sydney University's NICM Health Research Institute, said.

    Australia cannabis update: Investor takeaway

    Expectations for the Australian cannabis market continue to bubble up as significant changes take place.

    In its half-year report, the team at FreshLeaf said:

    These shifts are beginning to take shape: multiple regulatory changes are underway impacting patient access and product quality, there has been a flurry of M&A activity, and some industry players have altered their focus in the value chain as the market begins to move away from vertical integration.

    Investment interest in Australian cannabis will continue to oscillate depending on results seen in the market, but halfway through 2021 it's clear it has been one of the industry's most important years so far.

    Don't forget to follow us @INN_Australia for real-time news updates!

    Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

    Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

    https://www.linkedin.com/in/bryan-mc-govern-b23495b0/
    bmcgovern@investingnews.com
    The Conversation (0)
    Go Deeper
    AI Powered
    Cannabis leaf over map of Australia.

    A State-by-State Guide to Cannabis in Australia

    Person touching a cannabis plant; Australia map in flag colours.

    ASX Cannabis Stocks: 10 Biggest Companies

    Bryan Mc Govern

    Bryan Mc Govern

    Senior Editor

    Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.

    Latest News

    Incentive Regime for HMW Project in Argentina

    EUR Sells 0.5m CRML Shares for U$1.8m (A$2.7m)

    Trading Halt

    Lo Herma Drilling Permit & Contract Confirmed

    Sarama Resources Completes Mt Venn Gold Project Acquisition

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Australia Investing Stocks

    extractX

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×
    Bryan Mc Govern

    Bryan Mc Govern

    Senior Editor

    Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.

    Full Bio

    Follow

    Learn about our editorial policies.